Evommune (EVMN) stock surges as the company posts a mid-stage trial win for its experimental drug targeting atopic dermatitis ...

The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely ...

An eczema drug from Nektar Therapeutics maintained skin responses in a one-year study, meeting and in some cases exceeding ...

High-frequency wands use low-level electrical currents to kill acne-causing bacteria and reduce inflammation. At-home devices offer more convenience but less dramatic results than in-office ...

‘Melania’ declines 67% at domestic box office—one week after beating its projections US snowboard star Chloe Kim calls for unity after Trump bashes teammate over immigrant crackdown Retired FBI agent ...

The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...

Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...

Kennedy has made healthy eating a centerpiece of his Make America Healthy Again policy agenda in the last year. He frequently ...

IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadershipWill build ...

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive compl ...